Real-world comparison of chemotherapy plus bevacizumab with or without immunotherapy as first-line therapy in colorectal cancer

doi:10.3748/wjg.v31.i24.108298

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 24

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (34)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series, Tables (1-7) series.

Item

Count

PDF

HTML

Figures (1-7)

Tables (1-7)

Sum=33

Jun 28, 2025 (publication date) through Jun 26, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Jun 28, 2025; 31(24): 108298
Published online Jun 28, 2025. doi: 10.3748/wjg.v31.i24.108298

Table 4 Treatment-emergent adverse events in the 103 patients of the matched dataset, n (%)

Toxicities	Experimental group (n = 25)			Control group (n = 78)			P value for grade 1-2	P value for grade 3-4
Toxicities	Grade 0	Grade 1-2	Grade 3-4	Grade 0	Grade 1-2	Grade 3-4	P value for grade 1-2	P value for grade 3-4
Anemia	13 (50.0)	12 (50.0)	0 (0)	53 (70.6)	24 (28.2)	1 (1.2)	0.1831^a	1^b
Neutropenia	18 (69.2)	6 (26.9)	1 (3.8)	40 (51.8)	30 (38.8)	8 (9.4)	0.2807^a	0.4488^b
Leukocytopenia	19 (73.1)	5 (23.1)	1 (3.8)	47 (60.0)	28 (36.5)	3 (3.5)	0.2164^a	1^b
Thrombocytopenia	18 (69.2)	7 (30.8)	0 (0)	44 (55.3)	30 (40.0)	4 (4.7)	0.4782^a	0.5698^b
Proteinuria	23 (92.3)	2 (7.7)	0 (0)	64 (81.2)	14 (18.8)	0 (0)	0.3454^b	1^b
Aspartate transaminase increased	12 (46.2)	13 (53.8)	0 (0)	46 (57.6)	30 (40.0)	2 (2.4)	0.3363^a	1^b
Alanine transaminase increased	14 (53.8)	11 (46.2)	0 (0)	50 (63.5)	26 (35.3)	1 (1.2)	0.4667^a	1^b
Alkaline phosphatase increased	18 (69.2)	7 (30.8)	0 (0)	62 (77.6)	16 (22.4)	0 (0)	0.6126^a	1^b
Blood bilirubin increased	22 (84.6)	3 (15.4)	0 (0)	57 (64.7)	20 (34.1)	1 (1.2)	0.07312^b	1^b
Triglycerides increased	13 (50.0)	10 (42.3)	2 (7.7)	53 (67.1)	22 (29.4)	3 (3.5)	0.3894^a	0.5926^b
Hypothyroidism	23 (92.3)	2 (7.7)	0 (0)	78 (100)	0 (0)	0 (0)	0.0571^b	1^b
Nausea	11 (42.3)	14 (57.7)	0 (0)	31 (41.2)	46 (57.6)	1 (1.2)	0.9765^a	1^b
Vomiting	11 (42.3)	14 (57.7)	0 (0)	47 (58.8)	30 (40.0)	1 (1.2)	0.1901^a	1^b
Fatigue	23 (92.3)	2 (7.7)	0 (0)	58 (72.9)	20 (27.1)	0 (0)	0.09078^b	1^b
Fever	24 (96.2)	1 (3.8)	0 (0)	77 (98.8)	1 (1.2)	0 (0)	0.4283^b	1^b
Rash	23 (92.3)	2 (7.7)	0 (0)	78 (100)	0 (0)	0 (0)	0.05711^b	1^b
Diarrhea	24 (96.2)	1 (3.8)	0 (0)	72 (92.9)	4 (4.7)	2 (2.4)	1^b	1^b
Peripheral neurotoxicity	24 (96.2)	1 (3.8)	0 (0)	75 (96.5)	2 (2.4)	1 (1.2)	0.5698^b	1^b
Hand-foot syndrome	23 (92.3)	1 (3.8)	1 (3.8)	72 (92.9)	5 (5.9)	1 (1.2)	1^b	0.4283^b
Hypertension	24 (96.2)	1 (3.8)	0 (0)	77 (98.8)	0 (0)	1 (1.2)	0.2427^b	1^b

^aP values were calculated by χ² test.

^bP values were calculated by Fisher’s exact test.

The control group received chemotherapy combined with bevacizumab. The experimental group received chemotherapy combined with bevacizumab and anti-programmed death 1 immunotherapy.

Citation: Gao Z, Wang XY, Shen ZG, Liu JH, Wang XY, Wu SK, Jin X. Real-world comparison of chemotherapy plus bevacizumab with or without immunotherapy as first-line therapy in colorectal cancer. World J Gastroenterol 2025; 31(24): 108298
URL: https://www.wjgnet.com/1007-9327/full/v31/i24/108298.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i24.108298